[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spinocerebellar-degeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spinocerebellar-degeneration":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100596029",false,"NCT07040137","Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration","Phase III Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration","Inclusion Criteria:\n\n* Japanese SCD patients with mild to moderate ataxia\n\nExclusion Criteria:\n\n* Patients with secondary ataxia\n* Patients with clinically significant hepatic, renal, or cardiovascular dysfunction","ALL","18 Years",{"count":18,"type":19},142,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study to evaluate the efficacy and safety of KPS-0373 given once daily after breakfast in 142 patients with spinocerebellar degeneration . This study consists of the 4-week screening period, 24-week treatment period, and 4-week follow-up period.",[25],"Spinocerebellar Degeneration","RECRUITING","2025-06-25",{"date":29,"type":30},"2025-06-27","ACTUAL",{"date":32,"type":19},"2025-07",{"date":34,"type":19},"2027-03-31",{"name":36,"class":37},"Kissei Pharmaceutical Co., Ltd.","INDUSTRY",""]